Compositions and methods for treating skin conditions
AssigneeThe Trustees of Columbia University in the City of New York
InventorsVirginia Cornish, Amirhossein JAFARIYAN
Life of this patent
Estimating the term…
Abstract
The disclosed subject matter provides for genetically modified cells, e.g., fungal cells, that autonomously generates and/or secretes one or more skin therapeutics, and methods of use thereof. In certain embodiments, the present disclosure provides genetically-engineered fungal cells that generate and secrete growth factors, protease inhibitors, cytokines and/or chemokines and methods of use thereof, e.g., for treating skin conditions.
Claims99
A pharmaceutical composition comprising:
- (i) a live fungal cell genetically engineered to express and secrete a skin therapeutic and (ii) a pharmaceutically acceptable carrier.
A topical pharmaceutical composition comprising a hydrogel comprising a live fungal cell genetically engineered to express and secrete a skin therapeutic.
A pharmaceutical composition comprising:
- (i) a first live fungal cell genetically engineered to express and secrete a first skin therapeutic;
- (ii) a second live fungal cell genetically engineered to express and secrete a second skin therapeutic;
- and
- (iii) a pharmaceutically acceptable carrier,
- wherein the first skin therapeutic and the second skin therapeutic are different.
A pharmaceutical composition comprising:
- (i) a first live fungal cell genetically engineered to express and secrete a first skin therapeutic;
- (ii) a second live fungal cell genetically engineered to express and secrete a second skin therapeutic;
- (iii) a third live fungal cell genetically engineered to express and secrete a third skin therapeutic;
- and
- (iv) a pharmaceutically acceptable carrier,
- wherein the first skin therapeutic, the second skin therapeutic and the third skin therapeutic are different.
A pharmaceutical composition comprising:
- (i) a first live fungal cell genetically engineered to express and secrete a first skin therapeutic;
- (ii) a second live fungal cell genetically engineered to express and secrete a second skin therapeutic;
- (iii) a third live fungal cell genetically engineered to express and secrete a third skin therapeutic;
- (iv) a fourth live fungal cell genetically engineered to express and secrete a fourth skin therapeutic;
- and
- (v) a pharmaceutically acceptable carrier,
- wherein the first skin therapeutic, the second skin therapeutic, the third skin therapeutic and the fourth skin therapeutic are different.
A pharmaceutical composition comprising:
- (i) a first live fungal cell genetically engineered to express and secrete a first skin therapeutic;
- (ii) a second live fungal cell genetically engineered to express and secrete a second skin therapeutic;
- (iii) a third live fungal cell genetically engineered to express and secrete a third skin therapeutic;
- (iv) a fourth live fungal cell genetically engineered to express and secrete a fourth skin therapeutic;
- (v) a fifth live fungal cell genetically engineered to express and secrete a fifth skin therapeutic;
- and
- (vi) a pharmaceutically acceptable carrier,
- wherein the first skin therapeutic, the second skin therapeutic, the third skin therapeutic, the fourth skin therapeutic and the fifth skin therapeutic are different.
Dependencies are inferred from the claim text.